Daniel Timmermann’s Post

⭐ Join the team at Citeline for an exclusive webinar titled "Pharma R&D Annual Review" on May 21, 2024, at 10 AM EDT. ⭐ What is it? Pharmaprojects’ annual review of trends in pharmaceutical R&D takes the temperature of the industry at the start of 2024 by assessing the pipeline by company, therapeutic area, disease, target, and emerging drug modalities and regional variations.    ⭐ What will you learn? An understanding of how the pharma R&D climate is changing, where the pressure is rising and falling, and determine which parts of the industry are likely to be basking in sunshine and which may be preparing for unsettled conditions. This original research uses the gold-standard dataset of Pharmaprojects to support clinical planning, competitive intelligence, and market landscape assessments.    Please follow this link below for more details and to register: Citeline Citeline Clinical Citeline Commercial https://lnkd.in/euwN_3zv

📦Delivering new medicines through the clinic & on to patients has become increasingly challenging as molecules have become more complex & multiple modalities are explored. ➡️Drug delivery technologies are now critical enablers. 🗣️Hear directly from our Founder & CEO Christian Cobaugh on how we are working with innovators across #mRNA & other delivery technologies to help researchers achieve clinical outcomes & successful commercial launches.

By its math, Merck & Co. (far right below) spent the most on R&D in 2023 while Novo Nordisk (far left) had one of the most modest R&D budgets in Big Pharma. Eli Lilly and Company was also relatively thrifty with R&D. And yet the latter two are currently dominating the metabolic disease market. The link below can go full screen if you want to look at it without squinting: https://lnkd.in/eDktxd5R

It might surprise people that most primary and secondary CI knowledge actually sits in the archives and is often not used in strategy documents (original form) such as IPS (Integrated Product Strategy, a 5-year long-term brand plan) or War Games (scenario plans). At AdametNext, we understand the strategic requirements of marketing teams; hence, our deliverables are always 90 to 100% ready for strategic meetings. This is only possible due to the prior inside-out pharma brand management knowledge we gained while working with the CXO or brand directors.

We recently hosted a session at Nordic Life Science Days 2024, where industry leaders gathered to discuss the challenges and opportunities in advancing patient centricity within the pharmaceutical sector.   Despite the ongoing efforts across the industry to address patient needs throughout drug discovery, development, and commercialization, significant gaps remain. These challenges include identifying unmet needs early on, navigating increasingly complex clinical trials, and ensuring product availability.   Dr. Ulrica Sehlstedt, Arthur D. Little’s Global Leader for the Healthcare & Life Sciences practice, moderated a panel featuring Christophe Bourdon, CEO of LEO Pharma; Kati Kaijasilta, Business Development Director at Orion Pharma Ltd; Mike Ryan, General Manager Europe at EVERSANA; and Dr. Holger Kissel, Senior Vice President Scientific Relations and Liaison at BioNTech SE. Together, they explored how leading pharmaceutical companies are working to overcome these challenges to enhance patient value and achieve commercial success.   The discussions were insightful, and while we are encouraged by the innovative progress being made, it is clear there is still much work ahead. We look forward to continuing to collaborate across the industry to drive further improvements for patients.   #NLSDays #HealthcareInnovation #PatientCentricity

Thoughts on this? >> Roche says it is undeterred by upcoming biosimilar threat to Vabysmo >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharma #healthcare #pharmaceutical

Tomorrow, May 21st is the day. Join us for Pharma R&D Annual Review Webinar. Guaranteed to be informative and entertaining! #pharmaResearch #pharmaR&D #citeline, #researchanddevelopment

Groundbreaking Drug Approvals in September Underscore Pharma's Relentless Innovation [Free Excel Download at https://lnkd.in/gwXMqaa8] Leading the wave of breakthroughs, Bristol Myers Squibb's Cobenfy made history as the first new mechanistic approach to schizophrenia treatment in over 70 years. Sanofi and Regeneron's Dupixent became the first-ever biologic approved for COPD, the world’s third biggest killer. Zevra Therapeutics' Miplyffa and IntraBio Inc's Aqneursa became the first-ever approved therapies for the ultra-rare Niemann-Pick disease type C. Read more at: https://lnkd.in/g87K8fS5 #PipelineProspector Sept 2024 - Pharma & Biotech Monthly Recap by PharmaCompass.com #schizophrenia #stockmarket #pharmastocks #pharmaceuticalindustry #pharmanews #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmaceuticals #pharma #biotech #pharmacompass

Groundbreaking Drug Approvals in September Underscore Pharma's Relentless Innovation [Free Excel Download at https://lnkd.in/gwXMqaa8] Leading the wave of breakthroughs, Bristol Myers Squibb's Cobenfy made history as the first new mechanistic approach to schizophrenia treatment in over 70 years. Sanofi and Regeneron's Dupixent became the first-ever biologic approved for COPD, the world’s third biggest killer. Zevra Therapeutics' Miplyffa and IntraBio Inc's Aqneursa became the first-ever approved therapies for the ultra-rare Niemann-Pick disease type C. Read more at: https://lnkd.in/g87K8fS5 #PipelineProspector Sept 2024 - Pharma & Biotech Monthly Recap by PharmaCompass.com #schizophrenia #stockmarket #pharmastocks #pharmaceuticalindustry #pharmanews #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmaceuticals #pharma #biotech #pharmacompass

🌍 On #RareDiseaseDay, we stand in solidarity with the millions of people worldwide living with rare diseases. Erika Spens, Director of #RegulatoryAffairs, dives into how the EU and the US protect #OrphanDrugs, ensuring patients can access the vital treatments they need. Market exclusivity is a key incentive for #pharmaceutical companies to develop therapies for rare diseases, which might otherwise be overlooked due to the smaller patient populations. Learn more about what Cytel can do for #RareDiseases: https://bit.ly/49xoAQt #biotech #pharma #pharmaceuticalindustry #clinicaldevelopment #drug #drugdevelopment #FDA #EMA